D
Daniel J. Lenihan
Researcher at Vanderbilt University Medical Center
Publications - 166
Citations - 9052
Daniel J. Lenihan is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Heart failure & Cancer. The author has an hindex of 32, co-authored 140 publications receiving 6193 citations. Previous affiliations of Daniel J. Lenihan include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Courtney M. Campbell,Samantha LoRusso,Angela Dispenzieri,Arnt V. Kristen,Mathew S. Maurer,Claudio Rapezzi,Olivier Lairez,Brian M. Drachman,Pablo García-Pavía,Martha Grogan,Doug B Chapman,Leslie Amass,Michele Emdin,Mazen Hanna,Olga Azevedo,Calogero Cirami,Daniel Jacoby,J. González Costello,David Slosky,H. Moelgaard,Scott L. Hummel,Jose Nativi-Nicolau,Srinivas Murali,Nowell M. Fine,Eun-Seok Jeon,Sanjiv Shah,Ronald M. Witteles,Daniel J. Lenihan,Márcia Waddington Cruz,Yoshiki Sekijima,Jose A. Tallaj,Christopher Mueller,Johan Van Cleemput,Violaine Planté-Bordeneuve,Hans L A Nienhuis,Dianna Quan,D. Eric Steidley,Hartmut Schmidt,Jonas Wixner,Michael Polydefkis,Jeffrey W. Ralph,Hector O. Ventura,Saša Živković,Burkhard Gess,R. Torrón,Stephen S. Gottlieb,William Cotts,James M. Tauras,Nitasha Sarswat,Juan González Moreno,Yesim Parman,Jinju Luo +51 more
TL;DR: In this article , the authors examined sex differences in patients with ATTR-WT amyloidosis from the Transthyretin Amyloids Outcomes Survey (THAOS).
Journal ArticleDOI
Exercise right heart catheterization for pulmonary hypertension identified on screening echocardiography in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort.
Gregory T. Armstrong,James J. Tolle,Robert N. Piana,Aimee Santucci,James S. Leathers,Kirsten K. Ness,Daniel A. Mulrooney,Daniel M. Green,Vijaya M. Joshi,Leslie L. Robison,Melissa M. Hudson,Daniel J. Lenihan +11 more
TL;DR: Cardiopul pulmonary exercise testing further defined the magnitude and etiology of cardiopulmonary limitations in this life‐threatening late effect.
Journal ArticleDOI
Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma
Robert F. Cornell,Bonnie Ky,Brendan M. Weiss,Liping Du,Joseph R. Carver,Adam D. Cohen,Brian G. Engelhardt,Alfred L. Garfall,Stacey Goodman,Shelton L. Harrell,Adetola A. Kassim,Trafina Jadhav,Madan Jagasia,Javid Moslehi,Rupal O'Quinn,Michael R. Savona,David Slosky,Amanda M. Smith,Edward A. Stadtmauer,Dan T. Vogl,Racquel Innis-Shelton,Adam Waxman,Daniel J. Lenihan +22 more
TL;DR: This is the first prospective study designed to systematically evaluate cardiac events in patients receiving carfilzomib or bortezomib for multiple myeloma and found that CVAEs were more common with Car than with Bor but usually did not require discontinuation of therapy with careful management.
Journal ArticleDOI
Getting the SCOOP—Survey of Cardiovascular Outcomes From Oncology Patients During Survivorship
TL;DR: It is demonstrated that CS have self‐reported CV symptoms and there may be unmet needs for CV preventive services, which is important to identify gaps in CV care of CS.
Journal ArticleDOI
Prediction and early detection of anthracycline-related cardiotoxicity using cardiac biomarkers.
Patrick L Stevens,Daniel J. Lenihan,Bonnie Ky,Carla L. Warneke,Marcy M. Johnson,Vandana G. Abramson,Ingrid A. Mayer,Paul T. Adams,Mark G. Campbell,Puneet S. Cheema,Dennis F. Moore,Chilakamarri Yeshwant,Joseph R. Carver,Michael J. Fisch +13 more
TL;DR: The overall objective of this study was to define the utility of cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI) in the identification of subsequent ANTH cardiotoxicity.